|Folha de dados||Análises||Produtos relacionados||Protocolos|
|Recombinant Human EGFR / HER1 / ErbB1 protein (Catalog#10001-H08H)|
|0.2 μm filtered solution in PBS with 5% trehalose|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human EGFR / HER1 / ErbB1 (rh EGFR / HER1 / ErbB1; Catalog#10001-H08H; NP_005219; Met1-Ser645). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.|
|Human EGFR / HER1 / ErbB1|
No cross-reactivity in ELISA with
|ICC/IF, IF, FCM|
FCM: 0.5-2 μg/Test
ICC/IF: 5-20 μg/mL
|This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.|
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
As a member of the epidermal growth factor receptor (EGFR) family, EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF-α, betacellulin, etc. EGFR protein plays a crucial role in signaling pathway in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR protein homo- or heterodimerization, the subsequent tyrosine autophosphorylation and initiates various down stream pathways (MAPK, PI3K/PKB and STAT). In addition, EGFR signaling also has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently.